<DOC>
<DOCNO>EP-0643575</DOCNO> 
<TEXT>
<INVENTION-TITLE>
METERING SPRAY DESIGNED FOR PERNASAL APPLICATION
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31565	A61K31198	A61K912	A61K31137	A61K900	A61K900	A61K31185	A61K31565	A61K31135	A61K912	A61K31135	A61K31137	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K9	A61K31	A61K9	A61K9	A61K31	A61K31	A61K31	A61K9	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Use of at least one sex hormone or at least one 
precursor of a sex hormone in the metabolic process or 

at least one derivative of a sex hormone or of a 
combination 
thereof, apart from the precursors of 
testosterone or of dopamine, a dopamine derivative, 

NADH, NADPH or a combination thereof for producing a 
medicament in the form of a dispensing spray for 

pernasal application for controlled dosage reduction or 
for facilitating the passage through the blood-brain 

barrier. 
Use according to claim 1, characterised by a 
dosage between 2 and 20 mg active principle per spray 

burst. 
</CLAIMS>
</TEXT>
</DOC>
